News Algiax non-opioid drug works in chronic neuropathic pain A GABA-targeting drug developed by German Biotech Algiax has shown proof of concept in a chronic neuropathic trial trial.
News Vertex weakens after neuropathic pain trial reads out A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.
News Lilly adds to non-opioid pain pipeline with Confo deal Deal covers an AT2R inhibitor, a class that has been plagued by safety and efficacy issues.
News Lilly adds to pain pipeline with Asahi Kasei licensing deal US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t
Partner Content Partner Content Registration opens for SMi’s leading Pain Therapeutics Confe... Registration opens for Pain Therapeutics
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
